Lymphomas

Published on 02/03/2015 by admin

Filed under Basic Science

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2083 times

51 Lymphomas

Key points

Lymphoma is cancer of the lymphatic system and accounts for approximately 3% of new cases of cancer reported in the UK each year. The primary cancerous cell of origin is the lymphocyte; as a result, there is often considerable overlap between lymphomas and lymphoid leukaemias. Lymphomas are subdivided into two main categories: Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). Both HL and NHL can be further classified based on histology.

The site of malignancy is usually a lymph node. Extranodal disease, most frequently of the stomach, skin, oral cavity and pharynx, small intestine and CNS, can occur and is more common in NHL than HL.

Hodgkin’s lymphoma

Hodgkin’s disease, now known as HL, was first described by Thomas Hodgkin in 1832. HL accounts for 30% of all lymphomas and has an incidence in the UK of 2.2 per 100,000 for women and 3.3 per 100,000 for men. It is predominantly a disease of young adults, having a peak incidence between the ages of 15 and 35 years.

Investigations and staging

Once the diagnosis has been made on biopsy, further investigations are needed to assess disease activity and the extent of its spread through the lymphoid system or other body sites. This is called staging and is essential for assessing prognosis, with cure rates for localised tumours (stage I or II) being much higher than those for widespread disease (stage IV). The staging of HL is assessed by the Cotswolds modification of the Ann Arbor classification system (Box 51.1). Information about prognostic factors such as mediastinal mass and bulky disease is included in the classification system. The tests required to establish the stage include a complete history, physical examination, FBC, urea and electrolytes (U and Es), chest X-ray and computed tomography (CT). Other useful tests include erythrocyte sedimentation rate (ESR), serum LDH and liver function tests (LFTs). Positron emission tomography (PET) can be used to detect active residual disease.

Box 51.1 Cotswolds modification of the Ann Arbor classification system for Hodgkin’s lymphoma

Clinical stage Defining features
I Involvement of a single lymph node region or lymphoid structure
II Involvement of two or more lymph node regions on the same side of the diaphragm
III Involvement of lymph node regions or structures on both sides of the diaphragm:

IV Involvement of extranodal site(s) beyond that designated E Modifying characteristics   A: no symptoms
B: fever, drenching sweats, weight loss
X: bulky disease
>one-third width of the mediastinum
>10 cm maximal dimension of nodal mass
E: involvement of a single extranodal site, contiguous or proximal to known nodal site
CS: clinical stage
PS: pathological stage

Management

HL is potentially curable and, in general, sensitive to both chemotherapy and radiotherapy; therefore, the two main goals of treatment are to maximise the likelihood of cure whilst minimising the risk of late toxicity such as infertility. Stage of disease is the biggest factor in treatment choice and outcome. The management of classic HL is determined by the stage of the disease, and this is summarised in Fig. 51.1. Localised NLPHL frequently involves one isolated lymph node and tends to be indolent (slow growing). If there are no risk factors, it can be treated with IFRT alone (30 Gy); all other types are treated as advanced (stage III or IV) classic HL.

In Europe, the treatment of classic HL is determined by whether the disease is staged as early favourable disease, early unfavourable disease, advanced disease or relapsed (see Box 51.2).

Advanced disease

Patients with advanced disease (stages III and IV) are treated with combination chemotherapy. The first widely used combination chemotherapy regimen was MOPP (mechlorethamine, vincristine (Oncovin), procarbazine and prednisolone) which produced a response rate of 80% and long-term disease-free survival of approximately 50%. ABVD has replaced MOPP chemotherapy as the regimen of choice as it is as effective but less toxic in terms of fertility, haematological toxicity, and the development of acute leukaemia and myelodysplasia. Six to eight cycles of ABVD is considered the current standard treatment for advanced disease.

Despite advances in HL, 30–40% of patients progress or relapse and respond poorly to salvage chemotherapy. A number of regimens have been investigated to both increase dose intensity and density of treatment, for example, BEACOPP (bleomycin, etoposide, Adriamycin (doxorubicin), cyclophosphamide, vincristine, procarbazine, prednisolone) and escalated BEACOPP (Table 51.1). In a trial comparing escalated BEACOPP, standard BEACOPP and COPP-ABVD, escalated BEACOPP demonstrated increased overall survival compared with the other two treatment arms but at the cost of significant toxicity (Engert et al., 2009). First-line escalated BEACOPP can only be recommended currently as part of a clinical trial. A study to investigate the role of BEACOPP and PET imaging in patients with advanced HL is under way and will close in 2012 (UK Clinical Research Network Study Portfolio, 2010).

Table 51.1 Combination chemotherapy regimens effective in the treatment of Hodgkin’s lymphoma

Regimen Dose and route Frequency
ABVD (28-day cycle)
Doxorubicin 25 mg/m2 i.v. Days 1 and 15
Bleomycin 10,000 iu/m2 i.v. Days 1 and 15
Vinblastine 6 mg/m2 i.v. Days 1 and 15
Dacarbazine 375 mg/m2 i.v. Days 1 and 15
BEACOPP escalated (21-day cycle)a
Bleomycin 10,000 iu/m2 i.v. Day 8
Etoposide 200 mg/m2 i.v. Days 1–3
Adriamycin (doxorubicin) 35 mg/m2 i.v. Day 1
Cyclophosphamide 1250 mg/m2 i.v. Day 1
Vincristine 1.4 mg/m2 i.v. (max. 2 mg) Day 8
Procarbazine 100 mg/m2 orally Days 1–7
Prednisolone 40 mg/m2 orally Days 1–14
BEACOPP standard dose (21-day cycle)a
Bleomycin 10,000 iu/m2 i.v. Day 8
Etoposide 100 mg/m2 i.v. Days 1–3
Adriamycin (doxorubicin) 25 mg/m2 i.v. Day 1
Cyclophosphamide 650 mg/m2 i.v. Day 1
Vincristine 1.4 mg/m2 i.v. (max. 2 mg) Day 8
Procarbazine 100 mg/m2 orally Days 1–7
Prednisolone 40 mg/m2 orally Days 1–14
ChlVPP
Chlorambucil 6 mg/m2 orally Days 1–14
Vinblastine 6 mg/m2 i.v. Days 1 and 8
Procarbazine 100 mg/m2 orally Days 1–14
Prednisolone 40 mg/m2 orally (max 60 mg) Days 1–14

a Escalated BEACOPP and standard BEACOPP have shown activity in Hodgkin’s lymphoma, but their usage is not standard in the UK.

Other options for patients unlikely to tolerate ABVD include ChlVPP (chlorambucil, vinblastine, procarbazine, prednisolone) and CHOP (cyclophosphamide, doxorubicin (hydroxydaonorubicin), vincristine (Oncovin), prednisolone, rituximab.

Salvage therapy for relapsed disease

Relapsed disease refers to disease progression after completion of primary treatment which resulted in a complete remission. Depending on previous treatment, options include salvage radiotherapy, salvage chemotherapy or high-dose chemotherapy with autologous stem cell support. In this procedure, stem cells are collected from the patient and returned following high-dose chemotherapy. Patients who relapse after initial radiotherapy alone have a good chance of cure with combination chemotherapy, at least equal to that of patients initially treated with chemotherapy for advanced disease. Occasionally, radiotherapy is used if the disease is localised and previously non-irradiated. Those who relapse after combination chemotherapy have a worse prognosis, although durable remissions can be obtained with further conventional therapy.

Length of remission following first-line chemotherapy influences the success of subsequent salvage therapy and so failure of chemotherapy can be used to classify disease and determine appropriate therapy. If the duration of remission was greater than 12 months (late relapse), then the patient can be re-treated with their initial chemotherapy, salvage regimen or considered for high-dose chemotherapy with autologous transplantation.

Commonly used chemotherapy salvage regimens are listed in Table 51.2. If relapse occurs less than a year after treatment (early relapse), then high-dose chemotherapy with autologous stem cell support should be considered. A patient who has never achieved complete remission (primary refractory disease) should receive high-dose chemotherapy with autologous stem cell support.

Table 51.2 Salvage chemotherapy regimens effective in the treatment of lymphoma

Regimen Dose and route Frequency
DHAP
Cisplatin 100 mg/m2 i.v. Days 1
Cytarabine 2000 mg/m2 i.v. 12 hourly Day 2
Dexamethasone 40 mg orally Days 1–4
ESHAP
Etoposide 40 mg/m2 i.v. Days 1–4
Methylprednisolone 500 mg/m2 i.v. Days 1–5
Cytarabine 2000 mg/m2 i.v. Day 1
Cisplatin 25 mg/m2 i.v. Days 1–4
ICE
Ifosfamide 5000 mg/m2 i.v. Day 2
Carboplatina AUC 5 i.v. Day 2
Etoposide 100 mg/m2 i.v. Days 1–3
IVE
Epirubicin 50 mg/m2 i.v. Days 1
Etoposide 200 mg/m2 i.v. Days 1–3
Ifosfamide 3000 mg/m2 i.v. Days 1–3

AUC, area under the curve; GFR, glomerular filtration rate.

a Carboplatin dose (mg) = target AUC (mg/mL × min) × (GFR (mL/min) + 25).

High-dose chemotherapy plus autologous stem cell support is associated with a 40–50% 5-year survival rate. However, the significant toxicity of autologous stem cell transplantation means that it should be reserved for patients in whom there is a clear increase in chance of cure. Allogeneic transplant is an option in patients relapsing after autologous transplant (Brusamolino et al., 2009).

Non-Hodgkin’s lymphoma

The NHLs are a heterogeneous group of lymphoid malignancies ranging from indolent, slow-growing tumours to aggressive, rapidly fatal disease. Paradoxically, the more aggressive NHLs are more susceptible to anticancer therapy. The overall incidence of NHL in the UK is 11 per 100,000 per year and accounts for approximately 3% of all cancers in the UK. The disease is rare in subjects under 30 years of age and the incidence steadily increases with increasing age; the median age at presentation is about 60. NHL is slightly more common in men than in women (1.5:1).

Histopathology and classification

There have been many attempts to classify the NHLs into histological categories that have clinical significance. Despite this, many problems and areas of confusion remain. Approximately 85% of NHLs are of B-cell origin, while 15% are of T-cell origin or are unclassifiable.

There are two classification systems in common use. The Working formulation, developed in 1982, divides the lymphomas into low, intermediate and high grade. More recently, the revised European–American lymphoma (REAL) classification system has been developed (Table 51.3) and adopted by the World Health Organization (Box 51.3) to classify the grade of lymphoma. The REAL/WHO classification incorporates some diagnoses not included in the Working formulation and is a list of lymphomas using morphology, immunophenotype, genotype and clinical behaviour. It recognises the three major categories of lymphoid malignancies: B-cell neoplasms, T-cell/natural killer cell neoplasms and HL. However, in practice, the clinical behaviour of lymphomas informs the treatment strategies employed as these are based on the initial classification into indolent (low grade) or aggressive (intermediate and high grade) NHL. A more biologically relevant classification of lymphoma using the REAL/WHO classification and immunological and molecular characteristics increases the diagnostic specificity and improves selection and targeting of therapy.

Table 51.3 Clinical grade and frequency of lymphomas in the REAL classification

Diagnosis % of all cases
Indolent lymphomas
Follicular lymphoma 22
Marginal zone B-cell, mucosa-associated lymphoid tissue 8
Chronic lymphocytic leukaemia/small lymphocytic lymphoma 7
Marginal zone B-cell nodal 2
Lymphoplasmacytic lymphoma 1
Aggressive lymphoma
Diffuse large B-cell lymphoma 31
Mature (peripheral) T-cell lymphomas 8
Mantle cell lymphoma 7
Mediastinal large B-cell lymphoma 2
Anaplastic large cell lymphoma 2
Very aggressive lymphomas
Burkitt’s lymphoma 2
Precursor T-lymphoblastic 2
Other lymphomas 7

Staging

Determining the extent of disease in patients with NHL provides prognostic information and is useful in treatment planning. Patients with extensive disease usually require different therapy from those with limited disease. The NHLs can be staged according to the Ann Arbor classification (see Box 51.1). In this system, NHL is defined as stage I, II, III or IV, stage I being disease limited to a single lymph node and stage IV being advanced disease, with involvement of extralymphatic sites. The International Prognostic Index (Table 51.4) uses the following factors as predictors of poor prognosis: elevated LDH, stage III or IV disease, greater than 60 years of age, the higher the number of extranodal sites involved and the Eastern Co-operative Oncology Group (ECOG) performance status of two or higher. Other prognostic factors include bulky disease, presence of B symptoms and transformation from low- to high-grade disease. Prognostic indicators are important because they inform the treatment plan to avoid overtreating those with good prognosis and undertreating those with poor prognosis.

Table 51.4 International prognostic index

Factor Adverse prognosis
Age ≥60 years
Ann Arbor stage III or IV
Plasma lactate dehydrogenase level Above normal
Number of extranodal sites of involvement ≥2
Performance status ≥ECOG 2 or equivalent

ECOG, Eastern Co-operative Oncology Group.

Treatment

When designing a treatment plan for an individual patient, various factors must be taken into account. These include the patient’s age and general health, the extent or stage of the lymphoma and the particular histological subtype. Indolent (low-grade) lymphoma tends to run a slow course and although it is not curable, patients survive for prolonged periods with minimal symptoms. Aggressive (high-grade) lymphomas result in death within weeks or months if untreated. These lymphomas, however, are very responsive to chemotherapy and up to 50–60% may be cured with combination chemotherapy (Fig. 51.3).

CD20 is essential for cell cycle regulation and cell differentiation. It is expressed on normal B-cells and the majority of malignant B-cell lymphomas. The introduction of rituximab, a monoclonal antibody with specificity for CD20, has changed the way patients with NHL are treated and is now incorporated into most chemotherapy regimens. The mechanism of action of rituximab is not fully understood but is thought to involve complement-mediated lysis of B-cells and antibody-dependent cellular cytotoxicity. Other potential mechanisms include induction of apoptosis and inhibition of cell cycle progression.

Indolent non-Hodgkin’s lymphoma

The median age at which patients present with indolent NHLs is 50–60 years, and generally patients have a good performance status. If left untreated, indolent NHL has a comparatively long survival (median: 9 years). Follicular lymphoma is the most common of the indolent lymphomas. For the minority of patients presenting with limited-stage disease (stage I), radiotherapy to the involved field is generally used. However, the majority (80%) of patients present with advanced disease (stages II–IV) where the aim of treatment is to reduce disease bulk and offer symptom relief. Rituximab, cyclophosphamide, vincristine, prednisolone (R-CVP) is used as the first-line treatment for advanced (stage III or IV) follicular lymphoma following the results of a study comparing R-CVP with CVP (cyclophosphamide, vincristine, prednisolone) (Marcus et al., 2005). This approach has been incorporated into national guidance (NICE, 2006). R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) can also be used as first-line treatment for young patients with aggressive disease and is an option in relapsed disease (Table 51.5).

Table 51.5 Chemotherapy regimens effective in the treatment of non-Hodgkin’s lymphoma

Drug Dose and route Day of administration
R-CHOP (21-day cycle)
Cyclophosphamide 750 mg/m2 i.v. Day 1
Doxorubicin (hydroxydaunorubicin) 50 mg/m2 i.v. Day 1
Vincristine (Oncovin) 1.4 mg/m2 (max 2 mg) i.v. Day 1
Prednisolone 100 mg orally Days 1–5
Rituximab 375 mg/m2 i.v. Day 1
R-CVP (21-day cycle)
Cyclophosphamide 750 mg/m2 i.v. Day 1
Vincristine (Oncovin) 1.4 mg/m2 (max 2 mg) i.v. Day 1
Prednisolone 100 mg orally Days 1–5
Rituximab 375 mg/m2 i.v. Day 1
FC (28-day cycle)
Fludarabine 40 mg/m2 orally Days 1–3
Cyclophosphamide 250 mg/m2 daily orally Days 1–3
CHOP (21-day cycle)
Cyclophosphamide 750 mg/m2 i.v. Day 1
Doxorubicin (hydroxydaunorubicin) 50 mg/m2 i.v. Day 1
Vincristine (Oncovin) 1.4 mg/m2 (max 2 mg) i.v. Day 1
Prednisolone 100 mg orally Days 1–5

For patients who are asymptomatic at diagnosis, adopting a ‘watch and wait’ policy with active monitoring and initiating treatment when symptomatic is an option. Patients could be considered for recruitment to clinical trials; there are on-going studies comparing R-CVP with R-FC (rituximab, fludarabine, cyclosphosphamide) followed by rituximab maintenance and investigating the benefit of bendamustine compared to R-CVP. If patients fail to tolerate the standard treatment options, an oral alkylating agent, for example, chlorambucil, with or without a steroid can be used. Repeated courses may be given.

Relapsed aggressive non-Hodgkin’s lymphoma

Combination chemotherapy with R-CHOP probably cures 40–60%. This, therefore, implies that over half of all patients have refractory disease or relapse after first treatment.

In younger patients with aggressive NHL, the aim will be to introduce remission with further chemotherapy, using an alternative, salvage regimen, and then to consolidate remission with high-dose therapy (HDT). HDT is usually supported by mobilised peripheral blood stem cells (PBSCs) and an autologous PBSC transplantation (auto-PBSCT). Lymphoma is the most frequent indication for auto PBSCT in Europe. The European Group for Blood and Marrow Transplantation (EBMT) suggests that the upper age limit for autologous transplantation is 65 years. HDT, with autologous stem cell support, is also used as part of primary treatment for younger patients with indolent lymphoma. Patients who receive HDT after their initial treatment can have progression-free survival rates of around 50% at 5 years.

To induce a remission in patients with aggressive lymphoma and relapsed disease, it may be reasonable to use the same or similar regimen used for front-line chemotherapy. However, in most cases, the regimen chosen introduces new agents that are potentially not cross-resistant with those used in the initial treatment regimen. There are several salvage regimens in use and they generally have response rates of between 40% and 70%. Examples of salvage regimens are ICE (ifosfamide, carboplatin, etoposide), ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) and DHAP (cisplatin, cytarabine, dexamethasone) (see Table 51.2). Gemcitabine, a pyrimidine analogue, may be of benefit for patients with relapsed or refractory disease after two lines of treatment. Gemcitabine is used in combination with other agents, such as cisplatin and methylprednisolone. Rituximab can also be added to these salvage regimens. PBSCs are usually harvested after the second course of the salvage regimen. Patients then receive a high-dose regimen such as BEAM (carmustine, etoposide, cytarabine, melphalan) (Table 51.6) conditioning prior to stem cell infusion (autograft). Patients should only undergo an autograft if they have demonstrated a response to salvage chemotherapy.

Table 51.6 Conditioning chemotherapy for autologous transplantation

Drug Dose and route Day of administration
BEAM
Carmustine 300 mg/m2 i.v. 6 days before reinfusion
Etoposide 200 mg/m2 i.v. 5–2 days before reinfusion
Cytarabine 200 mg/m2 12 h i.v. 5–2 days before reinfusion
Melphalan 140 mg/m2 i.v. 1 day before reinfusion
Reinfusion of stem cells   Day 0
LACE
Lomustine 200 mg/m2 orally 7 days before reinfusion
Etoposide 1000 mg/m2 i.v. 7 days before reinfusion
Cytarabine 2000 mg/m2 6–5 days before reinfusion
Cyclophosphamide 1800 mg/m2 i.v. 4–2 days before reinfusion
Reinfusion of stem cells   Day 0

Patient care

The chemotherapy regimens used to treat HL and NHL (see Tables 51.1 and 51.5) are usually administered on a hospital outpatient basis with the patient visiting the clinic regularly for assessment and treatment. The patient is monitored by FBCs carried out before each cycle of chemotherapy and at the ‘nadir’ between cycles. The nadir is when the blood count is at its lowest point, usually 10–14 days after the first day of chemotherapy. The interval between each cycle of chemotherapy enables normal body cells to recover before the patient receives further treatment. Disease response to treatment is monitored by repeating some of the diagnostic investigations, such as CT, at suitable intervals and the use of PET. If there is little or no response to treatment, a different chemotherapy regimen will be used or a decision made to withdraw from active therapy and provide optimum supportive care.

Supportive care

During a course of chemotherapy, the patient requires supportive care to minimise the adverse effects of treatment. The common adverse effects of the chemotherapy regimens discussed in this chapter are outlined in Table 51.7. These will occur to varying degrees depending on the combination of drugs and the doses used as well as individual patient factors.

Tumour lysis syndrome

The lymphomas are, in general, highly sensitive to chemotherapy. The resulting lysis of cells which occurs following initiation of chemotherapy may lead to hyperuricaemia, hyperkalaemia and hypocalcaemia in patients with bulky disease, and result in urate nephropathy. There is a high incidence of tumour lysis syndrome (TLS) in tumours with high proliferation rates and tumour burden such as Burkitt’s lymphoma and T-lymphoblastic lymphoma. The mainstay of TLS prevention is hydration with the patient encouraged to maintain a high fluid intake. Hyperuricaemia is controlled with allopurinol and close monitoring of renal function, serum urate levels and electrolytes. Allopurinol must be commenced before chemotherapy and continued until the tumour load has reduced and serum urate levels are normal. In aggressive forms of NHL, rasburicase, a recombinant urate oxidase, may be indicated as prophylaxis. Allopurinol should not be prescribed concurrently with rasburicase because it will inhibit the production of uric acid, the substrate for rasburicase.

Rasburicase can also be used to treat TLS but will only correct hyperuricaemia. Treatment of TLS should include vigorous hydration and diuresis. Historically alkaline diuresis has been recommended, but overzealous alkalinisation can lead to problems such as metabolic acidosis (Cairo and Bishop, 2004). Hypocalcaemia should be corrected if the patient is symptomatic, but this may increase calcium phosphate deposition. Hyperkalaemia and hyperphosphataemia should be corrected; patients may require haemofiltration or dialysis.

Bone marrow suppression

Myelosuppression is usually the dose-limiting factor with these regimens, and it is necessary to carry out FBCs before treatment to confirm that recovery has occurred. Each chemotherapy protocol should be referred to so as to ensure appropriate management. Generally, if the platelet count is below 100 × 109 L−1 and/or the absolute neutrophil count (ANC) is less than 1 × 109 L−1, the subsequent dose may be reduced or treatment delayed by a week.

Anaemia is treated with blood transfusions and thrombocytopenia with platelet transfusions as necessary. Erythropoietin administration reduces blood transfusion requirements and can improve quality of life. However, the evidence suggesting improvement in patient survival is inconclusive.

Neutropenia is the most life-threatening acute toxicity; the neutropenic patient is at constant risk from infections. Seemingly minor infections such as cold sores can spread rapidly, and infections not seen in the normal population, such as systemic fungal infections, can occur. Supportive measures involve reducing the risks and the aggressive treatment of any infectious episodes. The patient is counselled to avoid contact with people with infection or those who may be carriers. Most infections, however, are from an endogenous source such as the gut or skin. The patient is educated on the importance of good personal hygiene, mouth care, how to monitor body temperature and to report any febrile episodes immediately. Co-trimoxazole 960 mg may be prescribed as prophylaxis against Pneumocystis pneumonia in patients receiving chemotherapy for lymphomas, particularly in those receiving a regimen containing fludarabine. Thorough and frequent hand washing helps to prevent the transmission of opportunistic infection to the neutropenic patient.

Febrile neutropenia

A febrile episode in the neutropenic patient is an indication for immediate treatment with broad-spectrum intravenous antibiotics. Susceptibility to infection is likely when the neutrophil count is less than 1 × 109 L−1 with increasing risk at levels less than 0.5 × 109 L−1 and 0.01 × 109 L−1. Fever, usually defined as a temperature above 38 °C maintained for 1 h or 38.3 °C on one occasion, may be the only sign of infection. The patient should be assessed to determine the site of infection, if possible. Blood cultures from all venous access ports and any other appropriate cultures, for example, midstream urine sample and stool sample, are taken and then antibiotic therapy commenced. Blood cultures are taken prior to starting antibiotics to increase the likelihood of obtaining a positive culture. Infection with Gram-negative bacilli, for example, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa, and Gram-positive cocci, for example, coagulase-negative staphylococci, β-haemolytic streptococci, enterococci, and Staphylococcus aureus is probable in this situation. First-line therapy should cover these common pathogens. Options include carbapenems, a third-generation cephalosporin or antipseudomonal penicillin with or without an aminoglycoside. If the patient does not respond to this combination within 24–48 h, then second-line therapy, which may include a glycopeptide for Gram-positive cover, is commenced.

Gram-positive infections are becoming more common with the use of indwelling intravenous catheters. If positive microbiological cultures are found, the appropriate antibiotic can be prescribed on the basis of sensitivities; however, if the patient is responding to empiric therapy, the antibiotics should not be changed. Only one-third of suspected infections are ever confirmed, and the pathogen may not be isolated. The febrile episode may not be due to infection; non-infectious causes include blood transfusion and underlying disease.

Growth factor support

Patients with persistent neutropenia or those who have repeated admissions for neutropenic sepsis may be supported with granulocyte-colony-stimulating factor (GCSF). There is evidence that patients with lymphomas receiving a reduced dose of chemotherapy as a consequence of myelosuppression have a worse prognosis when compared with patients who receive full doses. GCSF is indicated as primary prophylaxis, before any episode of febrile neutropenia, for regimens where there is a high (>40%) incidence of febrile neutropenia. GCSF has been investigated as a prophylactic measure to increase the dose intensity of chemotherapy in regimens such as CHOP-14 (cyclophosphamide, hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), prednisolone at 14-day intervals) and BEACOPP-14 (bleomycin, etoposide, Adriamycin (doxorubicin) cyclophosphamide, vincristine, procarbazine, prednisolone at 14-day intervals).

Case studies

Case 51.1

Mr RB is a 50-year-old man receiving a course of fludarabine and cyclophosphamide (see Table 51.5) for mantle cell lymphoma. He has no other medical problems and has normal renal and hepatic function.

Answers

Answers

Answers

References

American Society of Clinical Oncology. Guideline for antiemetics in oncology: update 2006. J. Clin. Oncol.. 2006;24:2932-2947.

Brusamolino E., Bacigalupo A., Barosi G. Classical Hodgkin’s lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. Haematologica. 2009;94:550-565.

Cairo M.S., Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br. J. Haematol.. 2004;127:3-11.

Department of Health. HSC 2008/001: Updated National Guidance on the Safe Administration of Intrathecal Chemotherapy. London: Department of Health. 2008. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Healthservicecirculars/DH_086870

Diehl V., Thomas R.K., Re D. Part II: Hodgkin’s lymphoma – diagnosis and treatment. Lancet Oncol.. 2004;5:19-26.

Engert A., Diehl V., Franklin J., et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow up of the GHSG HD9 Study. J. Clin. Oncol.. 2009;27:4548-4554.

Marcus R., Imrie K., Belch A., et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-1423.

National Institute for Health and Clinical Excellence. Rituximab for Aggressive Non-Hodgkin’s Lymphoma. London: NICE. 2003. Available at: http://guidance.nice.org.uk/TA65/Guidance/pdf/English

National Institute for Health and Clinical Excellence. Rituximab for the treatment of follicular lymphoma. London: NICE technology appraisal guidance A 110, NICE. 2006. Available at http://www.nice.org. uk/nicemedia/pdf/TA110guidance.pdf

National Institute for Health and Clinical Excellence. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma. London: NICE technology appraisal guidance 137, NICE. 2008. Available at http://www.nice.org.uk/nicemedia/pdf/TA137guidance.pdf

Ng M., Waters J., Chau I., et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br. J. Cancer. 2005;92:1352-1357.

Souhami R., Tobias J., editors. Cancer and Its Management. Oxford: Blackwell Science, 1998.

Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology (American Society Hematology Education Program). 2009:507-519.

UK Clinical Research Network Study Portfolio RATHL. A Randomized Phase III Trial to Assess Response Adapted Therapy Using FDG-PET Imaging in Patients with Newly Diagnosed Advanced Hodgkin’s Lymphoma. Available at http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=4488, 2010.

West of Scotland Blood Cancer Network. Clinical Management Guidelines Hodgkin’s Lymphoma Version 3.0. Available at http://www.medednhsl.com/meded/clinicalgpp/pdf/WoSCAN_CMG_Hodgkins_v3_0_August_2009.pdf, 2009.